Randox Molecular Diagnostics (MDx) offers a range of Molecular Arrays and assay formats, providing diagnostic, prognostic and predictive solutions for a range of conditions including sexually transmitted infection, respiratory infection, coronary heart disease (CHD), familial hypercholesterolemia and colorectal cancer with many more applications currently in development.
The Randox STI multiplex array rapidly screens for the presence of 10 different STIs simultaneously from one patient sample. The simultaneous detection of these infections provides a comprehensive profile for each patient enabling the clinician to decide on the best treatment options, decreasing antibiotic misuse and the risk of the infection spreading.
The KRAS, BRAF, PIK3CA Array allows the clinician to simultaneously detect important mutations in the KRAS, BRAF and PIK3CA genes, enabling the appropriate selection of metastatic CRC patients for therapy.
The Cardiac Risk Prediction Array provides simultaneous genotyping of 19 SNPs for a reliable CHD risk assessment. Combining genotype information with common risk factors could allow accurate classification of patients and preventative therapies and lifestyle advice targeted to those who require it most.
The Randox FH Array provides rapid simultaneous detection of mutations within the LDLR, ApoB and PCSK9 genes. FH is a genetic disorder of lipoprotein metabolism characterised by high LDL levels and early onset of cardiovascular disease.
The Respiratory Multiplex Array is capable of simultaneously detecting 22 respiratory pathogens in individuals suspected of Respiratory Tract Infections (RTIs). Both viral and bacterial pathogens are detected at the same time, providing clinicians with a comprehensive patient profile and enabling correct action to be taken quicker.